| dc.contributor.author |
Platis, D |
en |
| dc.contributor.author |
Labrou, NE |
en |
| dc.date.accessioned |
2014-06-06T06:47:03Z |
|
| dc.date.available |
2014-06-06T06:47:03Z |
|
| dc.date.issued |
2006 |
en |
| dc.identifier.issn |
00219673 |
en |
| dc.identifier.uri |
http://dx.doi.org/10.1016/j.chroma.2006.06.047 |
en |
| dc.identifier.uri |
http://62.217.125.90/xmlui/handle/123456789/3363 |
|
| dc.subject |
Anti-HIV 2F5 monoclonal antibody |
en |
| dc.subject |
Downstream processing |
en |
| dc.subject |
Molecular farming |
en |
| dc.subject |
Protein purification |
en |
| dc.subject.other |
Anti-HIV 2F5 monoclonal antibody |
en |
| dc.subject.other |
Downstream processing |
en |
| dc.subject.other |
Molecular farming |
en |
| dc.subject.other |
Protein purification |
en |
| dc.subject.other |
Bioassay |
en |
| dc.subject.other |
Drug products |
en |
| dc.subject.other |
Extraction |
en |
| dc.subject.other |
Tobacco |
en |
| dc.subject.other |
Viruses |
en |
| dc.subject.other |
Antibodies |
en |
| dc.subject.other |
monoclonal antibody |
en |
| dc.subject.other |
plant extract |
en |
| dc.subject.other |
tobacco extract |
en |
| dc.subject.other |
unclassified drug |
en |
| dc.subject.other |
virus sialidase |
en |
| dc.subject.other |
aqueous solution |
en |
| dc.subject.other |
article |
en |
| dc.subject.other |
binding affinity |
en |
| dc.subject.other |
enzyme linked immunosorbent assay |
en |
| dc.subject.other |
evaluation |
en |
| dc.subject.other |
fractionation |
en |
| dc.subject.other |
Human immunodeficiency virus |
en |
| dc.subject.other |
molecular weight |
en |
| dc.subject.other |
pH measurement |
en |
| dc.subject.other |
priority journal |
en |
| dc.subject.other |
tobacco |
en |
| dc.subject.other |
transgenic plant |
en |
| dc.subject.other |
Chemical Fractionation |
en |
| dc.subject.other |
Chromatography, Affinity |
en |
| dc.subject.other |
HIV Antibodies |
en |
| dc.subject.other |
Humans |
en |
| dc.subject.other |
Hydrogen-Ion Concentration |
en |
| dc.subject.other |
Models, Biological |
en |
| dc.subject.other |
Phosphates |
en |
| dc.subject.other |
Plant Extracts |
en |
| dc.subject.other |
Plant Leaves |
en |
| dc.subject.other |
Plant Proteins |
en |
| dc.subject.other |
Plants, Genetically Modified |
en |
| dc.subject.other |
Polyethylene Glycols |
en |
| dc.subject.other |
Recombinant Proteins |
en |
| dc.subject.other |
Staphylococcal Protein A |
en |
| dc.subject.other |
Tobacco |
en |
| dc.subject.other |
Abstracts |
en |
| dc.subject.other |
Antibodies |
en |
| dc.subject.other |
Biological Tests |
en |
| dc.subject.other |
Drugs |
en |
| dc.subject.other |
Tobacco |
en |
| dc.subject.other |
Viruses |
en |
| dc.subject.other |
Human immunodeficiency virus |
en |
| dc.subject.other |
Human immunodeficiency virus 2 |
en |
| dc.subject.other |
Nicotiana obtusifolia |
en |
| dc.subject.other |
Nicotiana tabacum |
en |
| dc.subject.other |
Orthomyxoviridae |
en |
| dc.title |
Development of an aqueous two-phase partitioning system for fractionating therapeutic proteins from tobacco extract |
en |
| heal.type |
journalArticle |
en |
| heal.identifier.primary |
10.1016/j.chroma.2006.06.047 |
en |
| heal.publicationDate |
2006 |
en |
| heal.abstract |
In the present study, an aqueous two-phase partitioning system (ATPS) was developed and evaluated as an initial fractionation step for therapeutic antibodies and enzymes from tobacco extracts. A detailed study has been performed to analyze the effect of pH, ionic composition of the system, types of polymers and their molecular weight and concentration, on the partitioning behavior of tobacco proteins and human anti-human immunodeficiency virus (HIV) monoclonal antibody 2F5 (mAb 2F5). A polyethyleneglycol/phosphate (PEG/Pi) aqueous two-phase system composed of 12% (w/w) PEG 1500 and 13% (w/w) phosphate buffer, pH 5, was selected as the system with the highest selectivity of antibody over native tobacco proteins. Under selected conditions, sufficient purification (3-4-fold) with high recovery at the bottom phase (approximately 95%) was achieved for mAb 2F5. In addition, the system allows removal of plant-derived compounds, such as phenolics and toxic alkaloids. The antibody fraction may be directly applied to a Protein A affinity column without any further pre-treatment, thus allowing homogenous antibody preparation. Analysis of the purified antibody fraction by enzyme-linked immunosorbent assay (ELISA) and western blot showed that the antibody was fully active and free of degraded variants or modified forms. The efficacy of the system was further demonstrated using additional proteins and enzymes of therapeutic importance, such as neuraminidase (NA) from influenza virus and human anti-HIV monoclonal antibody 2G12 (mAb 2G12), and showed that the system may find wide applicability as an economic extraction strategy for the initial fractionation of biopharmaceuticals from transgenic tobacco plants. © 2006 Elsevier B.V. All rights reserved. |
en |
| heal.journalName |
Journal of Chromatography A |
en |
| dc.identifier.issue |
1-2 |
en |
| dc.identifier.volume |
1128 |
en |
| dc.identifier.doi |
10.1016/j.chroma.2006.06.047 |
en |
| dc.identifier.spage |
114 |
en |
| dc.identifier.epage |
124 |
en |